Maximizing Transaction Value from Data Utilization Services through Upselling and Cross-Selling
First written in FY2022. 7 of 11 entries say "Restated". Latest entry: 2026-08-05.
18 other companies' latest entry also says "Advanced".
- FY2026-H1RestatedAnnual report
「During the consolidated interim period, the number of client health insurance societies and the annual transaction value per customer of pharmaceutical companies and insurers using the services continued to increase year on year, and the business continued to expand.」
The company reiterated that annual transaction value per customer among pharmaceutical companies and insurance companies continues to increase year on year, but did not provide new transaction-value figures for the interim period. - FY2025RestatedAnnual report
「In this business, we focus on increasing transaction value per customer by offering pharmaceutical companies and insurance companies higher-value services through upselling and a broader range of data through cross-selling.」
The company reiterated its policy of increasing transaction value per customer through upselling and cross-selling. - FY2024-Q3RestatedAnnual report
「During the nine months ended the third quarter, the number of client health insurance societies and annual transaction value per customer at pharmaceutical companies and insurance companies using the data each continued to increase year on year, and the business continued to expand.」
The company reiterated that annual transaction value per customer among pharmaceutical companies and insurance companies continues to increase year on year, but did not provide new transaction-value figures. - FY2024-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, the number of client health insurance societies and annual transaction value per customer among the pharmaceutical companies and insurance companies using the services continued to increase year on year, and the business continued to expand.」
The company reiterated that annual transaction value per customer among pharmaceutical companies and insurance companies continues to increase year on year, but did not provide new transaction-value figures. - FY2024-Q1RestatedAnnual report
「During the three months ended the first quarter, the number of client health insurance societies and annual transaction value per customer at pharmaceutical companies and insurance companies using the data each continued to increase year on year, and the business continued to expand.」
The company reiterated that annual transaction value per customer among pharmaceutical companies and insurance companies continues to increase year on year. - FY2023AdvancedAnnual report
「In this business, we focus on increasing transaction value per customer by offering pharmaceutical companies and insurance companies higher-value services through upselling and a broader range of data through cross-selling. During the current consolidated fiscal year, in our relationship with pharmaceutical companies, transaction value per existing customer increased by 29%, while the number of customers increased by 24%.」
Through upselling and cross-selling, transaction value per existing pharmaceutical-company customer increased by 29%, while the number of customers increased by 24%. - FY2022First statedAnnual report
「Maximizing transaction value for data utilization services through value-added offerings (upselling) and expanding the range of data (cross-selling)」
The company explicitly stated its goal of increasing transaction value per customer through analytical environments, consulting and application development, in addition to existing ad hoc and database sales.